2月12日早间，京新药业（002020）在A股公告，公司已向香港联交所递交上市申请，这家最早专注于中间体与原料药领域，又随着时代发展向创新药转型 的老牌药企，正式踏上了"A+H"两地上市的旅程。据北京商报记者不完全统计，2026年开年仅40余日，已有约30家医药企业递表港交所。 药企扎堆赴港，"创新"成为关键词。上述30家企业中，13家为带有特殊标识"B"的未盈利的创新药、创新医疗器械企业。港交所对未盈利生物科技企业的上 市审核，始终锚定产品的创新性、管线的差异化、临床数据的扎实程度。即便在已盈利的企业阵营中，"创新"同样被屡屡提起。 此外，"A+H"频现也成为此轮药企赴港上市的显著特征。除了京新药业外，还有百普赛斯、迪哲医药、益方生物等A股公司已在年内递表。此外，还有信立 泰、海特生物两股已于年内官宣正在筹划赴港上市。 | 最新发布 申请人 | | | | --- | --- | --- | | 日期 | | | | 12/02/2026 | 仙乐健康科技股份有限公司 | | | | 12/02/2026 整体协调人公告-委任（经修订） 吧 | | | | 29/01/2026 申请版本（第一次呈交）全文档 ...

2026年2月12日星期四 ➢ 美就业大增；中国促央企算力投资。A股 偏强震荡。上证指数收涨0.09%报4131.98 点，深证成指跌0.35%，创业板指跌1.08%。 有色板块多行业大涨。恒指冲高回落， 香港恒生指数收涨0.31%报27266.38点， 恒生科技指数涨0.9%，恒生中国企业指数 上涨0.28%。贵金属、锂金属强劲上涨。 大市成交额2172.175亿港元。外盘方面， 欧洲三大股指收盘涨跌不一，美国三大 股指小幅收跌，道指跌0.13%报50121.4点， 标普500指数持平报6941.47点，纳指跌 0.16%。美国非农就业创逾一年最大增长， 失业率意外下降，交易员料美联储7月才 会降息。中国国资委呼吁央企积极扩大 算力有效投资。 资料来源：彭博 | 27266.38 | 0.31 | 6.38 | | --- | --- | --- | | 9268.18 | 0.28 | 3.98 | | 5499.99 | 0.90 | -0.29 | | 118.11 | -0.12 | -4.33 | | 4131.99 | 0.09 | 4.11 | | 14160.93 | -0.35 | 4.7 ...

Core Viewpoint - Jingxin Pharmaceutical (002020) has submitted an application for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange [1] Group 1 - The application was submitted on February 11 and the related documents were published on the Hong Kong Stock Exchange website on the same day [1]

Group 1 - The inquiry transfer market is experiencing rapid growth, with 12 A-share listed companies implementing share transfers since 2026, and many institutions reporting floating profits exceeding 30% [1] - Public and private funds are actively participating in the inquiry transfer market, indicating a shift towards a more stable and regular share transfer mechanism in China's capital market [1] - The banking sector is engaged in a competitive marketing push for wealth management products ahead of the Chinese New Year, reflecting operational pressures due to declining interest rates and a scarcity of quality assets [1] Group 2 - Regulatory scrutiny in the capital market has intensified, with a focus on misleading statements and financial fraud, resulting in a significant increase in penalties and investigations [2] - As of February 11, 2026, 13 listed companies and their actual controllers have been investigated, with an average of one company being penalized every three days [2] - The total dividend amount distributed by listed companies before the Spring Festival has reached a record high of 348.8 billion yuan, surpassing the previous year's total [2] Group 3 - Several retail companies have announced adjustments to service arrangements and delivery fees during the Spring Festival, indicating a trend of increased costs for consumers [3] - The automotive industry is shifting from a "policy-driven" approach to a "product-driven" strategy, focusing on consumer demand and innovation for high-quality development [4] - Some companies in the photovoltaic industry are halting or delaying investment projects due to changing market conditions, indicating a transition towards market consolidation [4] Group 4 - xAI has seen significant talent turnover, with two co-founders leaving the company, raising concerns about the stability of its core team [5] - Tesla is also experiencing a wave of executive departures, with a recent announcement from a vice president marking the latest in a series of high-profile exits [5] - Apple is facing challenges in upgrading its Siri virtual assistant, with delays in the release of anticipated features due to software issues [5] Group 5 - Over ten real estate companies have undergone executive changes since the beginning of 2026, reflecting strategic adjustments in response to business needs [5] - Estée Lauder has filed a lawsuit against Walmart for selling counterfeit products, highlighting ongoing issues with brand protection in the retail sector [6][7] - 聚能磁体 has initiated the IPO process, indicating a move towards public listing and capital raising [7]

Group 1 - The company has submitted an application for the issuance of overseas listed shares (H shares) to the Hong Kong Stock Exchange on February 11, 2026 [1] - The application materials for this issuance and listing have been published on the Hong Kong Stock Exchange website on the same day [1]

Group 1 - The company, Jingxin Pharmaceutical, announced that it submitted an application for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange on February 11, 2026 [1] - The application materials for this issuance and listing were published on the Hong Kong Stock Exchange website on the same day [1]

Group 1 - The company, Jingxin Pharmaceutical (002020), has submitted an application for the issuance of overseas listed shares (H shares) to the Hong Kong Stock Exchange on February 11, 2026 [1] - The application materials for this issuance and listing have been published on the Hong Kong Stock Exchange website on the same day [1]

Core Viewpoint - The company, Jingxin Pharmaceutical (002020.SZ), has submitted an application for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange on February 11, 2026 [1] Group 1 - The application materials for this issuance and listing have been published on the Hong Kong Stock Exchange website on the same day [1]

证券代码：002020 证券简称：京新药业 公告编号：2026013 浙江京新药业股份有限公司 关于向香港联交所递交境外上市股份（H 股）发行 上市申请并刊发申请资料的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 需要特别予以说明的是，本公告仅为境内投资者及时了解本次发行并上 市的相关信息而作出。本公告以及刊登于香港联交所网站的申请资料均不构 成也不得视作对任何个人或实体收购、购买或认购公司本次发行的境外上市 股份(H 股）的要约或要约邀请。 公司本次发行并上市尚需取得中国证券监督管理委员会、香港证监会和 香港联交所等相关政府机关、监管机构、证券交易所的批准、核准或备案， 并需综合考虑市场情况以及其他因素方可实施，尚存在不确定性。公司将根 据该事项的进展情况依法及时履行信息披露义务，敬请广大投资者注意投资 风险。 特此公告！ 浙江京新药业股份有限公司董事会 浙江京新药业股份有限公司（以下简称"公司"）已于 2026 年 2 月 11 日向香港联合交易所有限公司（以下简称"香港联交所"）递交了发行境外 上市股份（H 股）并在香港联交所主板挂牌上市（以下简称" ...

Company Overview - Jingxin Pharmaceutical (002020.SZ) is an innovation-driven pharmaceutical group focusing on two core disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases. The company combines the commercialization of existing products with the continuous advancement of its product pipeline [1] - The company has shifted its strategic focus on innovative drug development towards central nervous system diseases and cardiovascular and cerebrovascular diseases, with a product portfolio that includes over 60 approved drugs, covering generic drugs, innovative drugs, traditional Chinese medicine, and biological agents [2] Financial Performance - For the fiscal years ending December 31, 2023, 2024, and the ten months ending October 31, 2025, the company reported revenues of approximately RMB 3.999 billion, RMB 4.159 billion, and RMB 3.344 billion, respectively [5] - The net profit for the same periods was approximately RMB 623 million, RMB 719 million, and RMB 629 million [4] - The gross profit margins for the fiscal years were 49.2%, 48.5%, and 48.3% respectively [6] Product Segmentation - The revenue breakdown by business line for 2023 shows that the main sources of income are from the following segments: - Pharmaceuticals: RMB 2.326 billion (58.2%) - Network: RMB 956 million (23.9%) - Medical devices: RMB 637 million (16.0%) [2] Market Overview - The Chinese pharmaceutical market is projected to grow from RMB 1,447.9 billion in 2020 to RMB 1,629.7 billion by 2024, with a compound annual growth rate (CAGR) of 3.0%. By 2035, it is expected to reach RMB 3,103.4 billion, with a CAGR of 6.5% from 2025 to 2035, surpassing the global CAGR of 5.1% during the same period [8] - The market share of patented drugs is expected to increase from 44.6% in 2020 to 70.0% by 2035, while the market share of generic drugs will decline from 55.4% to 30.0% [8] Central Nervous System Market - The global central nervous system drug market is expected to grow from USD 233.7 billion in 2020 to USD 258.8 billion by 2024, with a CAGR of 2.6%. The Chinese market is projected to grow from approximately USD 32.2 billion in 2020 to USD 34.1 billion by 2024, with a CAGR of 1.4% [10] - The insomnia drug market in China is expected to maintain a size of around USD 1.7 billion from 2020 to 2024, with a CAGR of -1.0%. However, it is projected to grow to USD 3.5 billion by 2035, with a CAGR of 7.5% from 2025 to 2035 [12] Cardiovascular Market - The global cardiovascular drug market is expected to grow from USD 115 billion in 2020 to USD 124.6 billion by 2024, with a CAGR of 2.0%. It is projected to reach USD 182 billion by 2035, with a CAGR of 3.8% from 2025 to 2035 [13] - The Chinese cardiovascular drug market is expected to decline from USD 25.5 billion in 2020 to USD 24.9 billion by 2024, with a CAGR of -0.7%. However, it is anticipated to rebound to USD 36.9 billion by 2035, with a CAGR of 4.1% from 2025 to 2035 [13]